Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Loopworm is ramping up production at a facility in Bangalore capable of churning out 6,000t of silkworm and black soldier fly ...